Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes

Fernando Álvarez-Guisasola, Domingo Orozco-Beltrán, Ana M. Cebrián-Cuenca, Manuel Antonio Ruiz Quintero, Escarlata Angullo Martínez, Luis Ávila Lachica, Carlos Ortega Millán, Elena Caride Miana, Jorge Navarro-Pérez, Julio Sagredo Perez, Joan Barrot de la Puente, Francesc Xavier Cos Claramunt

Research output: Contribution to journalArticleResearch

3 Citations (Scopus)


© 2019 Treatment of diabetes mellitus type 2 (DM2) includes healthy eating and exercise (150 minutes/week) as basic pillars. For pharmacological treatment, metformin is the initial drug except contraindication or intolerance; in case of poor control, 8 therapeutic families are available (6 oral and 2 injectable) as possible combinations. An algorithm and some recommendations for the treatment of DM2 are presented. In secondary cardiovascular prevention, it is recommended to associate an inhibitor of the sodium-glucose cotransporter type 2 (iSGLT2) or a glucagon-like peptide-1 receptor agonist (arGLP1) in patients with obesity. In primary prevention if the patient is obese or overweight metformin should be combined with iSGLT2, arGLP1, or inhibitors of type 4 dipeptidylpeptidase (iDPP4). If the patient does not present obesity, iDPP4, iSGLT2 or gliclazide, sulfonylurea, recommended due to its lower tendency to hypoglycaemia, may be used.
Original languageEnglish
Pages (from-to)442-451
JournalAtención primaria (Barcelona. Ed. impresa)
Publication statusPublished - 1 Aug 2019


  • Antidiabetic drugs
  • Hyperglycemia
  • Type 2 diabetes


Dive into the research topics of 'Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes'. Together they form a unique fingerprint.

Cite this